JP2013508289A5 - - Google Patents

Download PDF

Info

Publication number
JP2013508289A5
JP2013508289A5 JP2012534359A JP2012534359A JP2013508289A5 JP 2013508289 A5 JP2013508289 A5 JP 2013508289A5 JP 2012534359 A JP2012534359 A JP 2012534359A JP 2012534359 A JP2012534359 A JP 2012534359A JP 2013508289 A5 JP2013508289 A5 JP 2013508289A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
nitrite
composition according
plasma concentration
maintained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012534359A
Other languages
English (en)
Japanese (ja)
Other versions
JP5758904B2 (ja
JP2013508289A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/052683 external-priority patent/WO2011047161A1/en
Publication of JP2013508289A publication Critical patent/JP2013508289A/ja
Publication of JP2013508289A5 publication Critical patent/JP2013508289A5/ja
Application granted granted Critical
Publication of JP5758904B2 publication Critical patent/JP5758904B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012534359A 2009-10-14 2010-10-14 ニトライトの医薬製剤及びそれらの使用 Expired - Fee Related JP5758904B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25148309P 2009-10-14 2009-10-14
US61/251,483 2009-10-14
PCT/US2010/052683 WO2011047161A1 (en) 2009-10-14 2010-10-14 Pharmaceutical formulations of nitrite and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015113882A Division JP6125567B2 (ja) 2009-10-14 2015-06-04 ニトライトの医薬製剤及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2013508289A JP2013508289A (ja) 2013-03-07
JP2013508289A5 true JP2013508289A5 (enExample) 2013-10-31
JP5758904B2 JP5758904B2 (ja) 2015-08-05

Family

ID=43855036

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012534359A Expired - Fee Related JP5758904B2 (ja) 2009-10-14 2010-10-14 ニトライトの医薬製剤及びそれらの使用
JP2015113882A Expired - Fee Related JP6125567B2 (ja) 2009-10-14 2015-06-04 ニトライトの医薬製剤及びそれらの使用
JP2017074888A Pending JP2017141275A (ja) 2009-10-14 2017-04-05 ニトライトの医薬製剤及びそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015113882A Expired - Fee Related JP6125567B2 (ja) 2009-10-14 2015-06-04 ニトライトの医薬製剤及びそれらの使用
JP2017074888A Pending JP2017141275A (ja) 2009-10-14 2017-04-05 ニトライトの医薬製剤及びそれらの使用

Country Status (10)

Country Link
US (4) US10463689B2 (enExample)
EP (1) EP2488035B1 (enExample)
JP (3) JP5758904B2 (enExample)
CN (2) CN107260756A (enExample)
AU (1) AU2010306755B2 (enExample)
CA (1) CA2777066C (enExample)
ES (1) ES2633618T3 (enExample)
IL (1) IL219155A0 (enExample)
IN (1) IN2012DN03428A (enExample)
WO (1) WO2011047161A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065142A2 (en) 2007-11-15 2009-05-22 Biomedical Research Foundation Of Northwest Louisiana Use of nitrite salts in chronic ischemia
WO2010147742A2 (en) 2009-06-18 2010-12-23 Theravasc Inc. Use of nitrite salts in treating tissue damage
CN107260756A (zh) * 2009-10-14 2017-10-20 瑟阿瓦斯克有限公司 亚硝酸盐/酯的药物制剂以及其应用
BR112014003414B1 (pt) * 2011-08-17 2021-09-21 Board Of Regents, The University Of Texas System Composição e sistema de entrega oral para aumento de níveis fisiológicos e terapêuticos de óxido nítrico
US8627204B2 (en) * 2011-10-18 2014-01-07 Microsoft Corporation Custom optimization of web pages
CN105358160A (zh) 2013-02-20 2016-02-24 瑟阿瓦斯克公司 亚硝酸盐的药物制剂及其用途
WO2014183108A1 (en) * 2013-05-10 2014-11-13 Nitromega Corp. Nutritional or dietary supplements containing fatty acids and nitrite
GB201309092D0 (en) * 2013-05-20 2013-07-03 Edixomed Ltd Transdermal delivery system
WO2017214157A1 (en) 2016-06-06 2017-12-14 Theravasc Inc. Pharmaceutical formulations of nitrite uses thereof
IL268804B2 (en) 2017-02-20 2023-04-01 Univ Louisiana State Hydrogen sulfide and/or nitrite for the treatment and prevention of atrial fibrillation
US11850271B1 (en) * 2023-05-16 2023-12-26 King Faisal University Topical skin cream
WO2026006722A1 (en) 2024-06-28 2026-01-02 The Regents Of The University Of Michigan Nitric oxide generating medical devices and methods

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914446A (en) * 1958-06-26 1959-11-24 Upjohn Co Nitrite stabilized ascorbic acid-cyanocobalamin compositions
US4650484A (en) * 1983-02-03 1987-03-17 Alza Corporation Method for treating ischemic conditions
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5278192A (en) * 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US6709681B2 (en) * 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5994444A (en) * 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US7015876B1 (en) * 1998-06-03 2006-03-21 Lear Corporation Heads-up display with improved contrast
WO2000003725A1 (en) 1998-07-14 2000-01-27 Paracelsian, Inc. Method for identifying and confirming consistent bio-functionality of natural compositions
JP2002535353A (ja) 1999-01-29 2002-10-22 ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク 医薬品組成物
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
US6314956B1 (en) 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
GB0119011D0 (en) * 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
EP1492509A1 (en) 2001-12-18 2005-01-05 ALZA Corporation Dosage form providing time-varying patterns of drug delivery
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
JP2005524676A (ja) * 2002-03-20 2005-08-18 ザ・ユニバーシティ・オブ・クイーンズランド 一酸化窒素供与体及びオピオイド鎮痛薬を含む方法及び組成物
CA2379211A1 (fr) * 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
WO2005004884A2 (en) 2003-07-09 2005-01-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
JP2007502831A (ja) * 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
WO2005023189A2 (en) 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060083824A1 (en) 2004-10-20 2006-04-20 Pbm Products Llc Nutritional supplements for glucose intolerant individuals
MX2007009690A (es) 2005-02-11 2007-10-15 Nolabs Ab Dispositivo, metodo y uso para tratamiento de neuropatias que implican oxido nitrico.
CA2608651A1 (en) 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
CA2641950A1 (en) * 2006-02-10 2007-08-23 Mannatech, Inc. All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
WO2007149520A2 (en) 2006-06-21 2007-12-27 Albert Einstein College Of Medicine Of Yeshiva University Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof
KR20100014853A (ko) 2007-02-26 2010-02-11 존 런드버그 아질산염 및 질산염의 신규 용도 및 이를 함유하는 조성물
CA2678093C (en) 2007-02-26 2017-10-24 Jon Lundberg Performance enhancing composition and use thereof
WO2008153762A2 (en) 2007-05-25 2008-12-18 N30 Pharmaceuticals, Llc S-nitrosothiol formulations and storage systems
EP2184986A4 (en) * 2007-08-06 2010-12-15 Trinity Lab Inc PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC PAIN AND PAIN RELATING TO NEUROPATHY
WO2009065142A2 (en) 2007-11-15 2009-05-22 Biomedical Research Foundation Of Northwest Louisiana Use of nitrite salts in chronic ischemia
US20090196930A1 (en) 2007-12-27 2009-08-06 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
WO2010036236A1 (en) 2008-09-23 2010-04-01 Baker Hughes Incorporated Anchor assembly
US8568793B2 (en) * 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
WO2010147742A2 (en) 2009-06-18 2010-12-23 Theravasc Inc. Use of nitrite salts in treating tissue damage
CN107260756A (zh) * 2009-10-14 2017-10-20 瑟阿瓦斯克有限公司 亚硝酸盐/酯的药物制剂以及其应用
US20130209584A1 (en) 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
WO2012135623A1 (en) 2011-03-31 2012-10-04 Theravasc Inc. Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
US20140112983A1 (en) 2011-04-14 2014-04-24 Theravasc Inc. Nitrite compositions and uses thereof
US9294956B2 (en) 2011-12-29 2016-03-22 Qualcomm Incorporated Application-server-assisted preemptive multicast bearer establishment for real-time low-latency applications

Similar Documents

Publication Publication Date Title
HRP20250480T1 (hr) Kombinacija dasatiniba i adagrasiba za primjenu u liječenju nesitnostaničnog raka pluća
RU2012147739A (ru) Пероральные составы, содержащие аналоги цитидина, и способы их использования
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2012502015A5 (enExample)
JP2012502047A5 (enExample)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2012193216A5 (enExample)
JP2015038135A5 (enExample)
MX2011007779A (es) Formulaciones galenicas de compuestos organicos.
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
SI2760821T1 (en) A salt salt of an anti-inflammatory substituted cyclobutenedione compound
WO2009034431A3 (en) Controlled-release dosage forms for varenicline
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
FI4212152T3 (fi) Sakubitriili-valsartaaniannostusohjelma kroonisen systolisen sydämen vajaatoiminnan hoitoon
JP2014503593A5 (enExample)
JP2009513713A5 (enExample)
WO2012020301A3 (en) Oral controlled release pharmaceutical compositions of blonanserin
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
NZ611026A (en) Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria
JP2016512247A5 (enExample)
WO2007145863A3 (en) Sustained release formulation of naltrexone
JP2016505050A5 (enExample)
JP2008088189A5 (enExample)